Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma.

Rare Tumors · 2021 · PMC8504645 · PMID 34646430

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

trending toward significanceno p-value reported

The difference in overall survival based on those with PMD versus those with PMR + SMD at cycle 3 was not significant; however, TTP was trending toward significance in those with PMR + SMD at cycle 3 versus those with PMD.

also in 580 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.